{"name":"German High-Grade Non-Hodgkin's Lymphoma Study Group","slug":"german-high-grade-non-hodgkin-s-lymphoma-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"R-CHOEP 14 with 12x Rituximab","genericName":"R-CHOEP 14 with 12x Rituximab","slug":"r-choep-14-with-12x-rituximab","indication":"High-grade non-Hodgkin's lymphoma","status":"phase_3"}]}],"pipeline":[{"name":"R-CHOEP 14 with 12x Rituximab","genericName":"R-CHOEP 14 with 12x Rituximab","slug":"r-choep-14-with-12x-rituximab","phase":"phase_3","mechanism":"R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.","indications":["High-grade non-Hodgkin's lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPeDNqVVFIWXpDVzl3WHZrdHBTRjdjNndiXzI2VVBzMXF3VjMyRk1OOHdNOUFEUGZFOVpYVUFhSXN2X3hSSW9fY0ZfUlJMTEJlN0NKdFpQako2UVJ1dG9nbW9wd0tPczdnZkZEbHRuQ1pRNS1UMWVPU1Ribm0zRnNnS3A1S2xuUTh2VkdMUFU5aUVYWm84VDgxVjQ2VUFyQmdBVU52Nl80UGtvNWpGZ1BudmEtWF9rNFB1OHBfY1k3cXZWSVlnQ1hrTGp1ZlUtcVBB?oc=5","date":"2025-12-02","type":"pipeline","source":"Reuters","summary":"Trump administration backs Bayer's bid to curb Roundup lawsuits - Reuters","headline":"Trump administration backs Bayer's bid to curb Roundup lawsuits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQclVORDlINF9URV9nNUpWWmFLMDVkMURkTHI5YVJ6NVU1Y0pFamJXdExieE9PY0ZQOFFRcUo3OTJPTUNRQTA4blZQOGl2T2FvNXFsWnRMTHZsMnJ2U1poNXJ3TjEyT1AyOGV1bVdxMk9iNmhJWXFKWGg3eldQQl9Ka21nRQ?oc=5","date":"2025-10-22","type":"pipeline","source":"Via Medica Journals","summary":"Progress in the diagnosis and treatment of diffuse large B-cell lymphoma — State of the art - Via Medica Journals","headline":"Progress in the diagnosis and treatment of diffuse large B-cell lymphoma — State of the art","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNUzlITkh0WWVYY2JqRmtZTWtPRzhOQlg4YjFTY292X0hpM1c1dWFwZVRIWHBKM3V3RE43c3VqUjZUcE1NY0hVeXdaUDNNRVhSNEx6cUp4X1J6TnlOUHVFaDVaX3EwTWE3WXdSekpwRUhzV0E0V1BCOEJRT1lkdXZyZ0d4eDI3S0RpWVdV?oc=5","date":"2025-07-10","type":"regulatory","source":"The Lancet","summary":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee - The Lancet","headline":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Har","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE56b3hJQ3JjdzNnMnlVMDBLTVV3d2RDODFtMlN3MVp1V084X3o5OFIzMm1XYk5nWk9odmRiNC1PTzZxeWRQLVNvY251aUQwaG81bXlPLXFXc0Q2Mm92WWc4?oc=5","date":"2025-03-26","type":"pipeline","source":"Nature","summary":"Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy | Blood Cancer Journal - Nature","headline":"Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPMVdTODZGdXFDeEpMcU1uSXFpeGdBSlUwRF9weThobk1RaEY0VFd5X0Q2bmoxcjRldXN0MGVlVnduc1FSREFWU3JETjNkR2RDblJRdHNzSUdPa3RtMU9NMmNhTF9kM0RUUXJRbHdJaG9IOXptSE1SekhfQmo2VlBXQ0hyaW53dG5ZM1E?oc=5","date":"2025-02-25","type":"pipeline","source":"The ASCO Post","summary":"Early-Stage Classic Hodgkin Lymphoma - The ASCO Post","headline":"Early-Stage Classic Hodgkin Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQXJCOV8ybXhCQm1ORmw4X3h2ZDg5d3lua2FJVjlCZExDenNzZVJTU04wd2xkU2Rac3IxMWEyaHNYTmpqX2NQREd1VURIdVF6LUhzOEYwWloxV1VwOGxOQUxadF90VlNPVFA2Q2pPM3FBWF9ETUM4aDF6SEYzR2t4djVjZHY3OXdtQ05z?oc=5","date":"2024-07-03","type":"regulatory","source":"The Lancet","summary":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial - The","headline":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORFhIbEhoMVh1YkpYakZfZW4wT0s4a2prdGJGMEZYaDVzdnM2Y1h0QkRDWFdhVG1VdWhZY2JGcnlxNGVGbGZ1SjlyNnoxTE5SOGJwUDhBOXRqR0Z0UFhrU2psU3hQSFhXN2xHZWpOYTBLSnZfT01aUnV1UG5sQkJOWmtueUNvM1RBTVJJYVZLUjBXeWM?oc=5","date":"2024-02-08","type":"pipeline","source":"Frontiers","summary":"Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome - Frontiers","headline":"Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBSemJYZzE3b3JoejVXcGpYV1lPUEhudmZTUVl0Z19UZjJ4b0NCOEx0eWNrTmpKOGlEbXRtMV9ONkhHaEFtR1ItUjRCMmtXZE1uekJBckh3?oc=5","date":"2023-01-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"C-X-C Motif Chemokine Receptor 4–Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma - jnm.snmjournals.org","headline":"C-X-C Motif Chemokine Receptor 4–Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBxUVR6aU91a19CQkxDUFFEM2NMa2FFTkdFdVVndGpNUmZzcVJCQ0N6SXdDTTh5enJrT3NQS2FEV215clhVcWc4TmVMSWJPUklyTHpIY1B1dC0?oc=5","date":"2022-12-12","type":"trial","source":"ASCO Publications","summary":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial | Journal of Clin","headline":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5acEw1WVlGQUcxbE9vUXNhZVVYZ3RBb1YyT1BXZjBiRUFvLVNVZklfRkVtejltSlczcXc2RXpOY3FOSGxBMFk0Yzc0TTFvVG9WVXJOTHRDZXliRmV5elFoRw?oc=5","date":"2022-07-13","type":"pipeline","source":"NEJM","summary":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma - NEJM","headline":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1WSjAzWkpEM2puQkdrc0VNbzRpSXR5WDIyeVpmS3Z6WmdnRzljQ3pHQ05BMkdYdEwtNnZyTVRrbnl3elpqTXo3dWpLUnhkR21BSHNSSzByb2JlSkZWU0FN?oc=5","date":"2022-06-22","type":"regulatory","source":"Nature","summary":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms - Nature","headline":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOdTVhRzFQZXQyWTNKLUwySS1jckFqVEdWeU9yRzdWNkxrcFQtNTgxMVluR2JKZUctZ01yMWFqT1UtZVQ2RVdobHk0ZC05MWNseWtiYWFGSGUwZmhrb1NWWm95cHd2NFF0T3FGVWg4ZEsxRFBCRDIyeHctb2tKZjgwenhKTQ?oc=5","date":"2020-06-11","type":"pipeline","source":"CancerNetwork","summary":"Lymphoma 2006: Classification and Treatment - CancerNetwork","headline":"Lymphoma 2006: Classification and Treatment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}